Verona Pharma Shares ENHANCE Study Insights at CHEST 2024
LONDON and RALEIGH, N.C. -- Verona Pharma plc (NASDAQ: VRNA) is excited to announce its participation in the upcoming CHEST Annual Meeting 2024.
Presentations on Ohtuvayre's Impact on COPD
At the event, Verona Pharma plans to showcase four oral presentations and two posters that delve into their Phase 3 ENHANCE studies featuring Ohtuvayre (ensifentrine). This innovative therapy represents a significant advancement in the maintenance treatment of chronic obstructive pulmonary disease (COPD).
Innovative Approach to COPD Treatment
Ohtuvayre is recognized as a first-in-class dual inhibitor of phosphodiesterase enzymes, combining bronchodilator and anti-inflammatory effects. This unique mechanism marks the first novel inhaled therapy for COPD in over twenty years, providing new hope for patients suffering from this chronic condition.
Results of the ENHANCE Studies
The studies have showcased compelling data emphasizing the efficacy and safety of Ohtuvayre across various patient subgroups. Notably, these analyses revealed substantial improvements in lung function, symptom management, and overall quality of life. Moreover, a noticeable reduction in exacerbation rates was recorded across differing severities of COPD.
Insights from Leading Experts
Dr. William Stringer, a prominent figure in the field, remarked on the potential of ensifentrine in transforming COPD care. Its multifaceted actions, including bronchodilation and reduction of inflammation, are particularly beneficial for smokers and former smokers, highlighting the urgent need for effective treatments.
Details of Presentations
Verona Pharma's focused dedication to highlighting unmet needs within COPD treatment will be evident through their presentations.
Oral Presentations Overview
Details on the following presentations will be shared:
- Ensifentrine's positive effects on lung function and overall quality of life in COPD patients
- Investigation into how ensifentrine reduces COPD-related healthcare usage over an extended period
- Pooled analysis illustrating ensifentrine’s efficacy in mitigating symptoms in moderate to severe COPD
- Data supporting ensifentrine's ability to decrease exacerbation risks
Posters to Showcase Research Findings
In addition to oral presentations, Verona Pharma will display two informative posters that focus on broader aspects of COPD treatment with ensifentrine:
Poster Insights
The posters will cover:
- The impact of ensifentrine on symptoms and quality of life in patients with varying smoking histories
- How ensifentrine addresses needs across different patient demographics
Company Overview: Verona Pharma's Mission
Verona Pharma is committed to developing groundbreaking therapies for chronic respiratory diseases, addressing significant medical needs. With its flagship product Ohtuvayre paving the way for innovative treatment options, the company is poised for growth in diverse areas of respiratory care.
Contact Information
For further inquiries, please reach out to:
Verona Pharma plc
Tel: +1-844-341-9901
Victoria Stewart, Senior Director of Investor Relations
Email: IR@veronapharma.com
Frequently Asked Questions
What is the significance of the ENHANCE studies?
The ENHANCE studies demonstrate Ohtuvayre’s effectiveness for COPD treatment, showing significant improvements for patients.
What is Ohtuvayre?
Ohtuvayre is a novel COPD therapy that acts as both a bronchodilator and anti-inflammatory, providing dual benefits.
What outcomes were presented at CHEST 2024?
Outcomes included improvements in lung function, symptom relief, and reduced hospitalization rates among COPD patients.
How does ensifentrine work?
Ensifentrine inhibits two key enzymes, aiding in bronchodilation and inflammation reduction, crucial for COPD management.
Who is presenting these findings?
Various experts from leading institutions, such as Wake Forest University and UT Health San Antonio, will present the findings.
